J&J's 2025 drug sales forecast should not be tripping up investors. There's so much else like

Johnson & Johnson (JNJ) reports a strong first quarter, with sales up more than 5.5% and earnings eking out an annual increase.

from US Top News and Analysis https://ift.tt/yB4v25i
https://ift.tt/FK6XYAW